Mecart has been chosen by New Jersey Innovation Institute (NJII), an NJIT corporation, for its GMP Cleanroom at its Cell and Gene Therapy Development Center.

The project represents a new GMP cleanroom of approximately 1,600ft² of ISO 7 space developed specifically for advanced cell and gene therapy processing and manufacturing operations. This project also will serve as a training facility and a venue for collaborating with local manufacturing.

“It’s an honor to work with such an innovative company that focuses on local collaboration with its technological resources, like this new cleanroom,” said Patrice Genois, general manager of Mecart and vice-president of PolR.

“When NJII approached Mecart, they were clear that lead time was crucial as was a very tight specification for their state-of-the-art GMP cleanroom. They had very aggressive goals, made more challenging when dealing with an institution with government ties, but we were ready for the challenge.  We are excited to work with the NJII and NJIT teams and help them exceed their goals with this new suite of cleanrooms,” said Charles Lipeles, vice-president of US Operations.

Haro Hartounian, PhD, NJII Senior Executive Director, Biotechnology and Pharmaceutical Innovation said: “We were excited to meet with the Mecart team, travel to Quebec City to visit with their leadership, and review the project in detail with them.  It has been a great experience thus far and we know that we picked the best partner for this critical project.”

Construction is planned to begin later this year and will be completed in Q1 of 2020.